Cenerimod
Appearance
Clinical data | |
---|---|
Other names | ACT-334441 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C25H31N3O5 |
Molar mass | 453.539 g·mol−1 |
3D model (JSmol) | |
| |
|
Cenerimod is an investigational new drug that is being evaluated for the treatment of systemic lupus erythematosus.[1] It is a sphingosine-1-phosphate receptor modulator.[2]
References
[edit]- ^ "Cenerimod - Idorsia Pharmaceuticals". AdisInsight. Springer Nature Switzerland AG.
- ^ Piali L, Birker-Robaczewska M, Lescop C, Froidevaux S, Schmitz N, Morrison K, et al. (December 2017). "Cenerimod, a novel selective S1P1 receptor modulator with unique signaling properties". Pharmacology Research & Perspectives. 5 (6). doi:10.1002/prp2.370. PMC 5723703. PMID 29226621.